Alto Neuroscience CEO gifts 400,000 ANRO shares

Alto Neuroscience, Inc. President and CEO Amit Etkin reported a bona fide gift of 400,000 shares of Common Stock on May 14, 2026.

Accepted by SEC EDGAR 05/15/2026 - 05:06 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Alto Neuroscience, Inc. President and CEO Amit Etkin reported a bona fide gift of 400,000 shares of Common Stock on May 14, 2026. The shares were transferred for estate planning purposes to the Bard on Haven Trust, an irrevocable trust for the benefit of his spouse and children, for no consideration. The trustee is independent, and Etkin has no voting, dispositive, or pecuniary interest in the trust’s holdings. After the gift, he directly holds 833,949 shares of Alto Neuroscience common stock.

Insider Trade Summary

400,000 shares gifted

Gift 1 txn

Insider Etkin Amit

Role PRESIDENT AND CEO

Type	Security	Shares	Price	Value
Gift	Common Stock	400,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 833,949 shares (Direct)

Footnotes (1)

1. F1. The reporting person transferred 400,000 shares for estate planning purposes to the Bard on Haven Trust, an irrevocable trust, for the benefit of his spouse and children as a bona fide gift for no consideration. The trustee of the trust is independent of the reporting person, and the reporting person does not have voting, dispositive, or pecuniary interest over any of the securities held by the trust.

Key Figures

Shares gifted: 400,000 shares Gift price per share: $0.0000 per share Shares held after transaction: 833,949 shares +2 more

5 metrics

Shares gifted 400,000 shares Bona fide gift of common stock on May 14, 2026

Gift price per share $0.0000 per share No consideration for gifted shares

Shares held after transaction 833,949 shares CEO’s direct Alto Neuroscience common stock holdings post-gift

Gift transactions count 1 transaction Single bona fide gift reported in Form 4

Total shares gifted in filing 400,000 shares Aggregate gifted shares from transactionSummary

Key Terms

bona fide gift, irrevocable trust, estate planning purposes, pecuniary interest, +1 more

5 terms

bona fide gift financial

"as a bona fide gift for no consideration"

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

irrevocable trust financial

"to the Bard on Haven Trust, an irrevocable trust, for the benefit"

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

estate planning purposes financial

"transferred 400,000 shares for estate planning purposes to the Bard"

pecuniary interest financial

"does not have voting, dispositive, or pecuniary interest over any"

voting, dispositive, or pecuniary interest financial

"does not have voting, dispositive, or pecuniary interest over any"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Alto Neuroscience (ANRO) report in this Form 4?

Alto Neuroscience reported that CEO Amit Etkin made a bona fide gift of 400,000 shares of common stock. The transfer was for estate planning purposes to an irrevocable family trust and involved no cash consideration or market sale.

How many Alto Neuroscience (ANRO) shares did the CEO gift and to whom?

CEO Amit Etkin gifted 400,000 Alto Neuroscience common shares to the Bard on Haven Trust. This irrevocable trust benefits his spouse and children, with an independent trustee overseeing the securities held in the trust.

Did the Alto Neuroscience (ANRO) CEO receive any payment for the 400,000-share transfer?

No payment was received for the 400,000-share transfer; it was a bona fide gift for estate planning. The shares were moved to an irrevocable trust, and the transaction price per share was reported as $0.0000.

Does the Alto Neuroscience (ANRO) CEO retain control over the gifted shares?

The CEO does not retain control over the gifted shares. The footnote states he has no voting, dispositive, or pecuniary interest in securities held by the Bard on Haven Trust, which has an independent trustee.

How many Alto Neuroscience (ANRO) shares does the CEO hold after the gift?

After the 400,000-share gift, CEO Amit Etkin directly holds 833,949 shares of Alto Neuroscience common stock. This figure represents his direct ownership position following the reported estate-planning transfer.

Is this Alto Neuroscience (ANRO) insider transaction a market sale of shares?

This transaction is not a market sale. It is reported as a bona fide gift, transferring 400,000 shares to an irrevocable family trust for no consideration, meaning no open-market selling occurred in connection with this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Etkin Amit

(Last) (First) (Middle)

C/O ALTO NEUROSCIENCE, INC.

650 CASTRO STREET, SUITE 450

(Street)

MOUNTAIN VIEW CALIFORNIA 94041

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alto Neuroscience, Inc. [ ANRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		G(1)		400,000	D	$0	833,949	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person transferred 400,000 shares for estate planning purposes to the Bard on Haven Trust, an irrevocable trust, for the benefit of his spouse and children as a bona fide gift for no consideration. The trustee of the trust is independent of the reporting person, and the reporting person does not have voting, dispositive, or pecuniary interest over any of the securities held by the trust.

Remarks:

	/s/ Erin R. McQuade, Attorney-in-Fact	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)